ARMI | BioFabUSA had a lot to celebrate in 2018 - project awards, new members, summits, BioFab Consulting, Technology & Education Workforce Development (EWD) roadmaps - and more! We want to thank our Members for a jam-packed year of activity!
What is in store for 2019? We turned to our Members for their predictions and this is what they said:
“2018 saw the publication of several ISO standards that can benefit the regenerative medicine community. Guidance on Cell Counting Methods (Part 1) was published in January 2018, while the end of the year brought the publication of a three-part ISO standard on ancillary materials present during the production of cellular therapeutic products. However, these and any other newly developed or revised standards are not useful unless those who can benefit from them understand the impact of the standard on their operations and can identify a clear path for its implementation. 2019 will see SCB’s downstream impact on the standard development process – encouraging the adoption of standards and helping stakeholders understand the benefits they can bring to their organizations”.
SCB Operations Program Manager
“Extensive efforts begun in 2018 to roadmap the future of Biofabrication education and workforce needs– coupled with further industry and academic guidance in 2019 - will ensure the skilled workforce required for our emerging industry.”
Dean, University of New Hampshire at Manchester
“Several companies—including a number of large pharmaceutical companies—have strengthened their commitment to beta cell replacement therapy for type 1 diabetes over the past year. As they hone their sources for beta cells and their strategies to protect these cells, we will gain valuable data that will form the basis for human clinical trials.”
Esther Latres, Ph.D.
JDRF Director of Research, and Lead, Beta Cell Replacement Program
“Synthetic scaffolds for wound healing and tissue engineering applications will demonstrate equivalent healing performance in the clinic compared to expensive biologic-derived scaffolds such as SIS, amnion, and decellurized tissue. As payers become increasingly focused on lower healthcare costs, more cost-effective medical products will make a groundswell in the clinic.”
Jed Johnson, Founder
"We will see significant advances in 3D printing of complex biologic scaffolds, functional tissue components and vascularized tissues"
CEO and Co-Founder, FluidForm
“Automation holds the key to taking regenerative medicine out of the lab and into full scale manufacturing. We see four disruptive technologies gaining greater acceptance in 2019: 1) Independent cart; 2) AI/ML Analytics; 3) Virtual Reality; and 4) Blockchain. These technologies will enable users to be flexible in their material movement, detect patterns and outliers in their data faster and more consistently, be more efficient in their process development via a virtual twin, and provide trusted and controlled tracking capabilities for autologous TERM products. In 2018 big strides were made automating bioreactors, and we hope to engage with more sensing technology companies in the coming year. These solutions and more will be available mid-2019 for member training and exploration at the new Regenerative Medicine Rockwell Solutions Center, in Manchester, NH. “
OEM, Functional Safety Engineer, Rockwell Automation